^
Association details:
| Biomarker: | ESR1 mutation + PIK3CA mutation + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
Published date:
05/17/2023
Excerpt:
For patients with prior CDK4/6 inhibitor treatment and a detectable ESR1 mutation, options include elacestrant, or other ET either alone or in combination with targeted agents such as alpelisib (for PIK3CA-mutated tumors) or everolimus.
Secondary therapy:
tamoxifen; Aromatase inhibitor; fulvestrant
DOI:
10.1200/JCO.23.00638
Source:
Title:
Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor .
Published date:
10/09/2021
Excerpt:
Cohorts A and B of the BYLieve trial included pre-/postmenopausal women with HR+, HER2-, PIK3CA-mut ABC who received CDK4/6i + AI (Cohort A) or CDK4/6i + FUL (Cohort B) as immediate prior therapy....At baseline, 26% (27/102) of pts in Cohort A and 26% (25/97) of pts in Cohort B had ESR1 mut detected. In Cohort A (ALP + FUL), a numerically lower PFS was observed in pts with ESR1-mut disease.....In Cohort B (ALP + LET), pts with ESR1mut disease had a shorter PFS compared with those without ESR1-mut disease.
Secondary therapy:
fulvestrant; letrozole
